Mode
Text Size
Log in / Sign up
N/A N=30 Treatment

Sleep and Daytime Use of Humidified Nasal High-flow Oxygen in COPD Outpatients

Pulmonary Disease, Chronic Obstructive · Hypercapnia · Hypoxia

Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcome: Primary: Use of Oxygen Therapy by HNHF-O2 at Home — 6.8 Hours

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Humidified nasal high flow with oxygen (Device)
Age
Adult, Older Adult · 40+ yrs
Sex
All
Sponsor
Temple University
Primary completion
Dec 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Use of Oxygen Therapy by HNHF-O2 at Home
6.8
SECONDARY
Spirometry
0.07
SECONDARY
Change in 6 Minute Walk Distance
18.8
SECONDARY
Breathlessness
4.25

Summary

Humidified Nasal High-flow with Oxygen (HNHF-O2) therapy has been reported to have acute beneficial effects in patients with hypoxemic respiratory failure who have been hospitalized. The usefulness of this therapy in the outpatient setting is unproven. This pilot study will test the feasibility of using this therapy in the outpatient setting and its effects on sleep.

Eligibility Criteria

Inclusion Criteria

  • admitted to the hospital for an acute exacerbation of COPD within the past 12 weeks
  • have COPD as the primary diagnosis
  • have smoked > 10 pack years.
  • receiving supplemental oxygen as part of their usual clinical care.
  • willing to give informed consent

Exclusion Criteria

  • upper airway or nasal problems that prohibit the use of high flow oxygen
  • current use (≤ 4 weeks of study entry) of any PAP-therapy (e.g., CPAP or NPPV)
  • sleep apnea as follows: STOPBang scores ≥ 5 or STOPBang score ≥ 2 plus BMI > 35 kg/m2; or Berlin questionnaire scores suggesting high likelihood of sleep apnea with increased risk of sleep-related accident (e.g., occupation as a commercial driver or pilot);
  • excessive daytime sleepiness (i.e., either of High (>15) score on the Epworth Sleepiness Scale or "fall asleep" accident or "near miss" accident in prior 12 months).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03221387). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search